Clinical trials: Tamoxifen
Osteoporosis
Enhancing Osteoporosis Therapy: Can We Open the Anabolic Window?
Current osteoporosis therapies produce a prompt increase in bone mass, followed by only modest or no further subsequent gains. This limitation, known as the "remodeling transient," reflects the "coupling" of bone resorption with…
- Trial name
- NCT01166958
- Testing
- Teriparatide, Raloxifene
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Bleeding, Implants
Treatment of Unfavorable Bleeding Patterns in Contraceptive Implant Users
The etonogestrel (ENG) subdermal contraceptive implant (ENG implant) is a highly effective method of preventing pregnancy, but it has bleeding side effects that make it unappealing for many women.
- Conditions
- Bleeding, Implants, Breakthrough Bleeding
- Trial name
- Tamoxifen/BTB (NCT02903121)
- Testing
- Tamoxifen, Tamoxifen (open label)
- Where
- United States
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Vulvar Atrophy
Study of Intravaginal Tamoxifen in PostMenopausal Women With VVA
The purpose of the study is to study the safety, PK and PD of Intravaginal Tamoxifen on postmenopausal women with vulvar vaginal atrophy.
- Trial name
- DARE-VVA1 (NCT05378269)
- Testing
- Tamoxifen
- Where
- 2 sites in Australia
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Daré Bioscience, Inc.
Breast Cancer, Mammographic Density
Karolinska Interventional Study of Mammograhic Density (Karisma-1)
A feasibility study, randomising to either 10 or 20 mg of tamoxifen. The primary aim is to identify the time to mammographic density change and piloting the procedures.
- Trial name
- Karisma-1 (NCT04079517)
- Testing
- Tamoxifen
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Karolinska Institutet
Polycystic Ovary Syndrome
Induction of Ovulation With Raloxifene or Clomiphene Citrate in Polycystic Ovarian Syndrome
The Polycystic Ovarian Syndrome (PCOS) is a common disorder related to ovulation problems. Clomiphene citrate (CC) is the drug of first choice for this condition.
- Trial name
- NCT00427700
- Testing
- clomiphene citrate, raloxifene
- Where
- Brazil
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Hospital de Clinicas de Porto Alegre
Risk Reduction, Mammographic Density Reduction
Low Dose Tamoxifen for Mammographic Density Reduction
KARISMA2 is a randomized, double-blinded, six-armed placebo controlled study to identify a low dose of tamoxifen, with less side-effects and a density reduction non-inferior to the standard dose of 20 mg.
- Trial name
- KARISMA2 (NCT03346200)
- Testing
- Tamoxifen Oral Tablet
- Volunteers
- 1,440 people, healthy volunteers welcome
- Sponsor
- Per Hall
Menorrhagia, Metrorrhagia
Tamoxifen to Reduce Unscheduled Bleeding in New Users of the Levonorgestrel-releasing Intrauterine System (LNG-IUS)
This study evaluates the ability of tamoxifen to improve frequent or prolonged bleeding in new users of the 52mg levonorgestrel-releasing intrauterine device (IUD).
- Conditions
- Menorrhagia, Metrorrhagia, Medicated Intrauterine Devices
- Trial name
- NCT02824224
- Testing
- Tamoxifen
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Pharmacokinetics
Open-Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Tamoxifen When Coadministered To Healthy Post-Menopausal Female Subjects
The goal of this study is to evaluate the effect of multiple doses of Desvenlafaxine SR on the pharmacokinetics of Tamoxifen and endoxifen when coadministered to healthy post-menopausal female subjects.
- Trial name
- NCT01189500
- Testing
- Tamoxifen, Tamoxifen and Desvenlafaxine Succinate Sustained Release
- Where
- 2 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Pfizer
Breast Cancer
Nutritional Supplements and Hormonal Manipulations for Breast Cancer Prevention
The overall hypothesis is that the combination of a low dose of the antiestrogen Raloxifene with omega-3 fatty acids will exert a synergistic breast cancer chemopreventive effect due to the crosstalk of their downstream cellular…
- Trial name
- NCT00723398
- Testing
- Lovaza 4gm oral, Raloxifene 60 Mg Oral Tablet, Raloxifene 30 Mg Oral Tablet
- Where
- United States
- Volunteers
- 266 people, healthy volunteers welcome
- Sponsor
- Milton S. Hershey Medical Center
High Background Uptake on MBI
Impact of Low-dose Tamoxifen on BPU
The study will examine whether changes in background parenchymal uptake (BPU) on molecular breast imaging (MBI) can be induced by short-term use of low-dose tamoxifen.
- Trial name
- NCT02979301
- Testing
- Tamoxifen
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Cognition, Aging
Cognition in the Study of Tamoxifen and Raloxifene
The purpose of this study is to assess the effects of tamoxifen and raloxifene on cognitive aging in selected cognitively-healthy women.
- Trial name
- Co-STAR (NCT00687102)
- Testing
- tamoxifen, raloxifene
- Where
- 134 sites in United States, Canada
- Volunteers
- 1,498 people, healthy volunteers welcome
- Sponsor
- Wake Forest University
Mammographically Dense Breast
Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast
This randomized phase II trial studies how well afimoxifene works in reducing the risk of breast cancer in women with mammographically dense breast. Estrogen can cause the growth of breast cancer cells.
- Trial name
- NCT03063619
- Testing
- Afimoxifene, Laboratory Biomarker Analysis, Questionnaire Administration
- Where
- 5 sites in United States
- Volunteers
- 194 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center